RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Acromegaly: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Structured Physiotherapy Improves Functional Outcomes in Acromegalic Arthropathy After Biochemical Remission: A Prospective Controlled Study.
Yilmaz Merve Korkmaz et al., Endocrine connections (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895208/
- 2.
Machine Learning Quantifies Within-Subject Facial Change in Acromegaly.
Ammar Ali et al., European journal of endocrinology (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42886865/
- 3.
Higher ARNT expression is associated with the sparsely granulated phenotype in somatotroph pituitary adenomas: An immunohistochemical study.
Călin Cristiana et al., Pituitary (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42888277/
- 4.
Pro- and anti-inflammatory cytokine dysregulation in the saliva of patients with acromegaly: a cross-sectional study.
Campelo Renata Carvalho et al., Pituitary (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42888286/
- 5.
Should radiotherapy be repositioned in the contemporary management of acromegaly?
di Filippo Luigi et al., Pituitary (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42888334/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
NCT03252353 · UNKNOWN · Phase 3 · Chiasma, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT03252353
- 2.
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
NCT00171730 · Completed · Phase 2 · Novartis Pharmaceuticals
Ages 18 to 80
https://clinicaltrials.gov/study/NCT00171730
- 3.
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
NCT00216398 · Completed · Phase 4 · Ipsen
Ages 18 and over
https://clinicaltrials.gov/study/NCT00216398
- 4.
Pegvisomant And Sandostatin LAR Combination Study
NCT00068029 · Completed · Phase 4 · Pfizer
Ages 18 and over
https://clinicaltrials.gov/study/NCT00068029
- 5.
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
NCT00068042 · Completed · Phase 4 · Pfizer
Ages 18 and over
https://clinicaltrials.gov/study/NCT00068042
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Acromegaly
Acromegaly is a rare hormonal disorder caused by excess growth hormone production, usually from a benign pituitary tumour. It leads to abnormal growth of hands, feet, and facial features, along with numerous systemic complications. An estimated 1,500 Australians live with acromegaly, and diagnosis is often delayed by a decade due to its gradual onset.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
BACKGROUND: Musculoskeletal symptoms frequently persist in acromegaly despite biochemical remission, yet the impact of structured physiotherapy on pain, stiffness, and function remains poorly defined. OBJECTIVE: To evaluate the effects of a standardized knee-focused physiotherapy program in controlled acromegaly and to identify clinical predictors of treatment responsiveness. METHODS: Thirteen patients with acromegaly in remission and 13 age-, gender-, and BMI-matched individuals with primary knee osteoarthritis completed a 15-session physiotherapy program. Outcomes were assessed pre- and post-intervention using the Brief Pain Inventory (BPI) and WOMAC. Minimal clinically significant difference (MCID) thresholds (≥2 for BPI, ≥10 for WOMAC) determined meaningful improvement. Correlation analyses examined associations between clinical variables and Δ scores. RESULTS: Acromegaly patients showed significant improvements in all BPI and WOMAC domains (p<0.001). MCID was achieved by 85% for BPI and 100% for WOMAC Total. Pain and function improved most, whereas stiffness showed limited responsiveness. Compared with osteoarthritis controls, acromegaly patients demonstrated smaller Δ changes; baseline-adjusted analyses (ANCOVA) indicated that this attenuated response was largely explained by greater baseline severity in the control group, whereas the persistently greater stiffness in acromegaly remained significant even after adjustment. BMI correlated positively with improvements in BPI Total (r = 0.63) and BPI Pain Severity (r = 0.69), while adenoma size correlated negatively with both measures (r = -0.57 and -0.60). BMI showed a negative association with WOMAC Total improvement (r = -0.59). Stiffness changes were strongly negatively correlated with pretreatment IGF-1 (r = -0.77). CONCLUSION: Structured physiotherapy yields clinically meaningful improvements in pain and function in acromegaly, while stiffness appears less reversible and more structurally driven. Early musculoskeletal assessment and physiotherapy integration may enhance long-term management.
Common Questions
What is Acromegaly?
Acromegaly is a rare hormonal disorder caused by excess growth hormone production, usually from a benign pituitary tumour. It leads to abnormal growth of hands, feet, and facial features, along with numerous systemic complications. An estimated 1,500 Australians live with acromegaly, and diagnosis is often delayed by a decade due to its gradual onset.
How many clinical trials are available for Acromegaly?
RareWays currently indexes 113 clinical trials for Acromegaly, of which 4 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Acromegaly come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Acromegaly.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.